PERJETA&reg; IV Infusion Drug use surveillance

PERJETA&reg; IV Infusion Drug use surveillance - PERJETA&reg; IV Infusion Drug use surveillance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017699

Enrollment

300

Registered

2015-05-27

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with breast cancer who are scheduled to start receiving PERJETA during this surveillance enrollment period.

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Safety;ADR occurence	—

Secondary

Measure	Time frame
Efficacy;Response rate per investigator assessment	—

Countries

Japan

Contacts

Public ContactAyaka Shimizu

Chugai Pharmaceutical Co., Ltd. Real World Data Science Dept.

shimizuayk@chugai-pharm.co.jp03-3273-0905

Outcome results